IP Library Granted Patent US 7,635,591
Granted Patent B2
US 7,635,591 · App. 10/595,620 · Granted Dec 22, 2009

Method for differentiating mesenchymal stem cell into neural cell and pharmaceutical composition containing the neural cell for neurodegenerative disease

Assignees: FCB Pharmicell Co., Ltd.; Hyun-Soo Kim
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,635,591
App. No.
10/595,620
Granted
Dec 22, 2009
Kind
B2
Abstract

The present invention provides a method of differentiating and proliferating a mesenchymal stem cell into the neural cell by culturing in a medium comprising an epidermal growth factor and a hepatocyte growth factor after confluent culture of the mesenchymal stem cell. The present invention provides more effective method of differentiating and proliferating the mesenchymal stem cell or the mononuclear cell comprising the mesenchymal stem cell into the neural cell with a neuron and an astrocyte in terms of time, efficiency and maturity as compared with conventional methods.

Claims (9)

1. A method of differentiating and proliferating a mesenchymal stem cell into a neural cell, said method comprising two steps of:

(1) confluent culturing the mesenchymal stem cell as a pretreatment and

(2) culturing a mesenchymal stem cell in a medium comprising growth factors,

wherein the growth factor are epithermal growth factor and hepatocyte growth factor;

whereby the confluent mesenchymal stem cell differentiates into a neural cell.

2. The method of claim 1 , wherein the mesenchymal stem cell is cultured for more than 1 week in a medium comprising about 1 to about 10,000 ng/ml by concentration of the epithermal growth factor and about 1 to about 10,000 ng/ml by concentration of the hepatocyte growth factor after confluent culturing the mesenchymal stem cell for about 1 to about 50 hours.

3. The method of claim 1 , wherein the mesenchymal stem cell is cultured for more than 1 week in a medium comprising about 10 ng/ml by concentration of the epithermal growth factor and about 20 ng/ml by concentration of the hepatocyte growth factor after confluent culturing the mesenchymal stem cell for about 24 hours.

4. The method of claim 1 , wherein the mesenchymal stem cell is cultured for about 2 weeks in the medium comprising growth factor, wherein the growth factor are epithermal growth factor and hepatocyte growth factor, and then the medium comprising the epithermal growth factor and the hepatocyte growth factor is changed with a medium consisting of the epithermal growth factor.

5. The method of claim 4 , wherein the mesenchymal stem cell is a mononuclear cell comprising the mesenchymal stem cell obtained from the bone marrow.

Assignments (2)
CHANGE OF NAME Recorded Jan 31, 2012
From: FCB PHARMICELL CO., LTD.
To: PHARMICELL CO., LTD.; KIM, HYUN-SOO
Reel/Frame 027621/0702 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 2, 2006
From: KIM, HYUN-SOO; KANG, YOUNG-MO; LEE, KYUNG-BOCK; PARK, SANG-KYO; LEE, SANG-KAP
To: FCB PHARMICELL CO., LTD.; HYUN-SOO KIM
Reel/Frame 017559/0733 →
Continuity (1)
Related Publication 20070054399A1 · Mar 8, 2007